Regeneron Raises Possibility Of Quick CRL Resolution For High-Dose Eylea
Executive Summary
On its earnings call, Regeneron said its 8mg formulation of aflibercept could obtain US FDA approval this quarter, despite receiving a complete response letter in June. Refiling’s fate tied to review of pozelimab, which is manufactured in the same plant with fill/finish concerns.